PFE – Pfizer Inc.
Pfizer, Inc.PFE
$24.32Name : Pfizer, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $138,610,475,008.00
EPSttm : 1.31
Pfizer, Inc.
$24.32
1.84%$0.44
PFE — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
2.85
Margin Of Safety %
44
Put/Call OI Ratio
0.85
EPS Next Q Diff
0.1
EPS Last/This Y
1.59
EPS This/Next Y
-0.13
Price
24.31
Target Price
28.88
Analyst Recom
2.48
Performance Q
-14.85
Upside
-30.5%
Beta
0.3
Ticker: PFE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-06-05 | PFE | 26.04 | 0.84 | 0.51 | 2670158 |
| 2026-06-08 | PFE | 25.61 | 0.85 | 0.22 | 2602290 |
| 2026-06-09 | PFE | 25.66 | 0.87 | 0.23 | 2626092 |
| 2026-06-10 | PFE | 25.61 | 0.88 | 0.49 | 2620685 |
| 2026-06-11 | PFE | 26.17 | 0.87 | 0.32 | 2627088 |
| 2026-06-12 | PFE | 26.21 | 0.86 | 0.98 | 2674358 |
| 2026-06-15 | PFE | 26.01 | 0.86 | 0.71 | 2540495 |
| 2026-06-16 | PFE | 26.05 | 0.86 | 1.27 | 2565700 |
| 2026-06-17 | PFE | 25.92 | 0.88 | 0.35 | 2618688 |
| 2026-06-18 | PFE | 25.23 | 0.86 | 0.98 | 2650457 |
| 2026-06-22 | PFE | 25.08 | 0.89 | 0.46 | 2124542 |
| 2026-06-23 | PFE | 24.75 | 0.87 | 0.93 | 2195376 |
| 2026-06-24 | PFE | 24.08 | 0.91 | 0.70 | 2273924 |
| 2026-06-25 | PFE | 23.69 | 0.90 | 1.47 | 2348334 |
| 2026-06-26 | PFE | 24.28 | 0.86 | 0.40 | 2339815 |
| 2026-06-29 | PFE | 24.39 | 0.89 | 0.36 | 2269090 |
| 2026-06-30 | PFE | 24.06 | 0.88 | 0.41 | 2303077 |
| 2026-07-01 | PFE | 23.89 | 0.86 | 0.47 | 2354245 |
| 2026-07-02 | PFE | 24.32 | 0.85 | 0.36 | 2383848 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-06-05 | PFE | 26.03 | -12.8 | 8487.3 | 2.96 |
| 2026-06-08 | PFE | 25.61 | -12.8 | 8066.3 | 2.96 |
| 2026-06-09 | PFE | 25.68 | -12.8 | 8908.8 | 2.96 |
| 2026-06-10 | PFE | 25.60 | -12.8 | 8818.7 | 2.96 |
| 2026-06-11 | PFE | 26.17 | -12.8 | 9196.6 | 2.96 |
| 2026-06-12 | PFE | 26.21 | -12.8 | 8897.1 | 2.96 |
| 2026-06-15 | PFE | 26.01 | -12.8 | 8766.8 | 2.96 |
| 2026-06-16 | PFE | 26.05 | -13.0 | 8900.0 | 2.96 |
| 2026-06-17 | PFE | 25.93 | -13.0 | 8816.4 | 2.96 |
| 2026-06-18 | PFE | 25.22 | -13.0 | 8483.4 | 2.96 |
| 2026-06-22 | PFE | 25.08 | -13.0 | 8800.6 | 2.96 |
| 2026-06-23 | PFE | 24.72 | -13.0 | 8668.7 | 2.96 |
| 2026-06-24 | PFE | 24.05 | -13.0 | 8486.9 | 2.96 |
| 2026-06-25 | PFE | 23.67 | -13.0 | 8645.8 | 2.96 |
| 2026-06-26 | PFE | 24.30 | -13.0 | 9248.5 | 2.96 |
| 2026-06-29 | PFE | 24.39 | -13.0 | 8941.7 | 2.96 |
| 2026-06-30 | PFE | 24.06 | -13.0 | 8704.4 | 2.96 |
| 2026-07-01 | PFE | 23.90 | -13.0 | 8779.7 | 2.96 |
| 2026-07-02 | PFE | 24.31 | -13.0 | 9141.5 | 2.96 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-06-05 | PFE | 0.00 | 1.23 | 2.77 |
| 2026-06-08 | PFE | 0.00 | 1.27 | 2.77 |
| 2026-06-09 | PFE | 0.00 | 1.27 | 2.77 |
| 2026-06-10 | PFE | 0.00 | 1.27 | 2.86 |
| 2026-06-11 | PFE | -0.03 | 1.27 | 2.86 |
| 2026-06-12 | PFE | -0.03 | 1.27 | 2.86 |
| 2026-06-15 | PFE | -0.03 | 1.29 | 2.86 |
| 2026-06-16 | PFE | -0.03 | 1.29 | 2.86 |
| 2026-06-17 | PFE | -0.03 | 1.29 | 2.86 |
| 2026-06-18 | PFE | -0.03 | 1.29 | 2.86 |
| 2026-06-22 | PFE | -0.03 | 1.29 | 2.86 |
| 2026-06-23 | PFE | -0.02 | 1.29 | 2.86 |
| 2026-06-24 | PFE | -0.02 | 1.29 | 2.86 |
| 2026-06-25 | PFE | -0.02 | 1.29 | 2.86 |
| 2026-06-26 | PFE | -0.02 | 1.29 | 2.85 |
| 2026-06-29 | PFE | -0.03 | 1.29 | 2.85 |
| 2026-06-30 | PFE | -0.03 | 1.29 | 2.85 |
| 2026-07-01 | PFE | -0.03 | 1.29 | 2.85 |
| 2026-07-02 | PFE | -0.03 | 1.29 | 2.85 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.75
Avg. EPS Est. Current Quarter
0.68
Avg. EPS Est. Next Quarter
0.85
Insider Transactions
-0.03
Institutional Transactions
1.29
Beta
0.3
Average Sales Estimate Current Quarter
14411
Average Sales Estimate Next Quarter
16148
Fair Value
35.05
Quality Score
80
Growth Score
45
Sentiment Score
57
Actual DrawDown %
60.6
Max Drawdown 5-Year %
-59
Target Price
28.88
P/E
18.64
Forward P/E
8.61
PEG
P/S
2.19
P/B
1.54
P/Free Cash Flow
14.61
EPS
1.3
Average EPS Est. Cur. Y
2.96
EPS Next Y. (Est.)
2.83
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
11.79
Relative Volume
1.32
Return on Equity vs Sector %
-19.2
Return on Equity vs Industry %
-30
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
9141.5
◆
PFE
Healthcare
$24.31
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
39.6
Range 1M
24.9%
Sup Dist
2.6%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-8.2%
EPS NY
-4.5%
52W%
21.7%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+42.7% upside
Upside
+42.7%
Quality
80
MoS
44%
PFE — P/E HistoricalDrug Manufacturers - General
Pfizer, Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 75000
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
PFE
Latest News
—
Caricamento notizie per PFE…
stock quote shares PFE – Pfizer Inc. Stock Price stock today
news today PFE – Pfizer Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PFE – Pfizer Inc. yahoo finance google finance
stock history PFE – Pfizer Inc. invest stock market
stock prices PFE premarket after hours
ticker PFE fair value insiders trading